Saffron Extract — Research Profile

For mild-to-moderate depression, yes — multiple randomized controlled trials have found 30mg saffron extract comparable to 20mg fluoxetine (Prozac) and 20mg citalopram (Celexa) in reducing depression scores. However, saffron has not been tested against higher SSRI doses or for severe depression. It should not replace prescribed medication without medical supervision, but it represents a legitimate evidence-based option for mild mood complaints.

Most clinical trials show significant improvements in mood scores within 4-6 weeks, similar to the timeline for conventional antidepressants. Some people report subjective improvements in outlook and sleep quality within the first 2 weeks. The affron extract (28mg) showed statistically significant mood improvements at 4 weeks in multiple trials.

Saffron extract supplements are standardized to contain specific concentrations of the active compounds crocin and safranal — typically 3.5% Lepticrosalides (affron) or 2% crocin. Cooking saffron threads vary widely in potency, and you would need to consume impractical amounts to match a standardized extract dose. Additionally, supplement-grade saffron is tested for purity, whereas culinary saffron is frequently adulterated with cheaper spices.

Nearly all positive human evidence uses a standardised stigma extract in capsule form dosed around 28-30 mg/day, so that is the best-supported format. A head-to-head safety trial found both the whole aqueous extract and the isolated crocin fraction were equally well tolerated at 30 mg/day, but there is no evidence that an isolated single compound outperforms the standardised whole extract for mood or sleep.

The strongest evidence is for mood: a meta-analysis of randomized trials in major depressive disorder found saffron clearly outperformed placebo (large effect size, ES ~1.62) and worked about as well as standard antidepressants, and a 12-week RCT confirmed improved depression scores in adults with depressive symptoms. Additional randomized support exists for premenstrual syndrome and for sleep quality in older adults. A non-randomized trial in children with ADHD found saffron comparable to methylphenidate, while for osteoarthritis a 50 mg/day RCT reduced an inflammatory marker but did not beat placebo on pain.

Most human trials use 28-30 mg of standardised extract per day - 28 mg in the affron mood studies and 30 mg (often split as 15 mg twice daily) in the PMS and sleep trials. Some conditions have used more, such as 50 mg/day for osteoarthritis, but there is no established benefit to exceeding roughly 30 mg/day for mood or sleep.

Time of day has not been directly compared in trials, and mood studies simply dosed once daily without specifying timing. The PMS trial split the 30 mg dose into 15 mg in the morning and 15 mg in the evening, and for sleep the 30 mg dose is reasonably taken in the evening; otherwise pick a consistent daily time that fits your routine.

At supplement doses saffron is well tolerated: a 12-week trial at 30 mg/day reported no serious side effects and no clinically significant changes in liver, kidney, thyroid, or blood counts (a small rise in white cells stayed within the normal range). The PMS trial likewise described only a tolerable adverse-effect profile; reported complaints across studies are generally mild and non-specific rather than a consistent set of severe effects.

Direct interaction studies are limited, but the most relevant caution is with antidepressants and other serotonergic drugs, because saffron matched standard antidepressants in head-to-head depression trials and additive mood effects have not been formally evaluated. Bleeding has only been described at toxic gram-level doses, and a controlled study cited in a toxicology review found saffron tablets (200-400 mg) had no adverse effect on the coagulation system, so a clinically meaningful bleeding interaction at supplement doses is not established. Anyone on prescription therapy, especially antidepressants, should still clear it with their prescriber.

The best-supported candidates are adults with mild-to-moderate low mood or subclinical depressive symptoms, women with premenstrual syndrome, and older adults with poor sleep, since these are where randomized trials show benefit. It has also been studied in children with ADHD (comparable to methylphenidate in a non-randomized trial), but that should be clinician-supervised. It should be avoided in pregnancy, where a human safety review notes that high doses have acted as an abortifacient through uterine stimulation.

Trials measure benefit over weeks rather than days: a standardised extract at 30 mg/day improved subjective sleep quality and shortened sleep-onset latency in older adults after 4 weeks, while mood studies assessed outcomes at 6-12 weeks (28 mg/day of the affron extract showed significant depression-score improvement by 12 weeks). Week-by-week onset has not been directly characterised, so expect a gradual effect over roughly one to three months rather than an immediate response.

The best controlled safety data extend to about 12 weeks: a double-blind trial giving 30 mg/day of saffron aqueous extract or crocin recorded no serious side effects and no meaningful changes in liver, kidney, thyroid, or blood-count labs, and a 12-week mood RCT at 28 mg/day was similarly well tolerated. Daily use beyond three months has not been rigorously studied, so safety over longer periods is not established.

Supplement trials use only about 28-50 mg of standardised extract per day, and 30 mg/day was tolerated for 12 weeks without serious adverse effects, so ordinary capsule doses sit far below any toxic threshold. A review of the human safety literature places toxic effects at roughly 5 g and above and an estimated lethal dose near 20 g - hundreds of times a typical supplement dose. The clearest hard limit is pregnancy: doses above about 10 g have historically acted as an abortifacient through uterine stimulation, so saffron should be avoided while pregnant even though supplement amounts are tiny by comparison.

Saffron has been studied inside multi-ingredient products without new safety problems - for example a sachet combining Crocus sativus extract with probiotics, prebiotics, and magnesium taken daily for six months in people with diabetes. The main theoretical caution is stacking it with other mood-active or serotonergic supplements, since saffron performs comparably to standard antidepressants in trials and additive effects have not been formally tested.

Choose a product standardised to the active compounds crocin and safranal rather than raw ground saffron, and match the dose used in trials - roughly 28-30 mg/day. The strongest evidence comes from named standardised extracts such as affron (28 mg) and the 30 mg extracts used in sleep and PMS studies, so a labelled extract with a stated standardisation is more reliable than an unquantified 'saffron powder'.